Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M79,279Revenue (TTM) $M23,002Net Margin (%)15.8Altman Z-Score1.7
Enterprise Value $M89,494EPS (TTM) $1.4Operating Margin %22.0Piotroski F-Score6
P/E(ttm)23.0Beneish M-Score-2.7Pre-tax Margin (%)16.1Higher ROA y-yY
Price/Book5.210-y EBITDA Growth Rate %-2.5Quick Ratio0.7Cash flow > EarningsY
Price/Sales3.65-y EBITDA Growth Rate %-12.5Current Ratio0.9Lower Leverage y-yY
Price/Free Cash Flow43.1y-y EBITDA Growth Rate %23.6ROA % (ttm)5.9Higher Current Ratio y-yN
Dividend Yield %4.5PEG--ROE % (ttm)25.0Less Shares Outstanding y-yN
Payout Ratio %101Shares Outstanding M2,530ROIC % (ttm)18.1Gross Margin Increase y-yY

Gurus Latest Trades with AZN

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

AZN is held by these investors:



AZN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ASTRAZENECA PLC10% Owner 2014-11-12Sell2,000,000$1784.29view

Quarterly/Annual Reports about AZN:

    News about AZN:

    Articles On GuruFocus.com
    Causeway International Value Buys AstraZeneca, Gildan Mar 09 2017 
    Dodge & Cox Comments on AstraZeneca Feb 06 2017 
    Dodge & Cox's Stock Fund 4th Quarter Commentary Jan 16 2017 
    Big Alzheimer Flop Creates Buying Opportunity for Eli Lilly Dec 10 2016 
    8 Uncommon Stocks NWQ Managers Is Buying Dec 06 2016 
    How Could a Potential Nexium Lawsuit Affect AstraZeneca? Nov 03 2016 
    Novo Nordisk Is Being Ignored Oct 06 2016 
    Novartis Is Surviving Oct 03 2016 
    10 Stocks Dodge & Cox Keep Buying Sep 22 2016 
    Dividend and Value Opportunities in the Large-Cap Pharmaceutical Space Apr 05 2016 

    More From Other Websites
    4:26 am AstraZeneca receives orphan designation from EMA for inebilizumab Mar 29 2017
    Tesaro won’t reveal price of its ovarian cancer drug. But it’ll likely be near $14,000 a month Mar 28 2017
    Company News for March 28, 2017 Mar 28 2017
    New Data Demonstrate RSV Immunoprophylaxis With SYNAGIS® (palivizumab) May Result in Reduced... Mar 28 2017
    AstraZeneca Shares Progress on LYNPARZA™ (olaparib) Tablets in the US Mar 28 2017
    BUZZ-AstraZeneca cancer drug faces new competition from Tesaro Mar 28 2017
    Tesaro Secures FDA Nod for Ovarian Cancer Drug Mar 28 2017
    First Trump Hiccups, Now Brexit Flare-Ups Coming For Stocks Mar 27 2017
    Tesaro Creeps Up On Rivals With Cancer Drug OK, But Merger Unlikely Mar 27 2017
    AstraZeneca's Lung Cancer Drug Tagrisso Approved in China Mar 27 2017
    AstraZeneca’s Lung Cancer Drug Secures China Approval (AZN) Mar 27 2017
    Chinese drug approval boosts AstraZeneca's lung cancer hopes Mar 27 2017
    Chinese drug approval boosts AstraZeneca's lung cancer hopes Mar 27 2017
    Chinese drug approval boosts AstraZeneca's lung cancer hopes Mar 27 2017
    Chinese drug approval boosts AstraZeneca's lung cancer hopes Mar 27 2017
    AstraZeneca wins approval for lung cancer pill in China Mar 27 2017
    New Lung Cancer Drug From AstraZeneca is Approved in China Mar 24 2017
    AstraZeneca Stock Rising in '17: What's Working in its Favor? Mar 23 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)